Due to the difference in LHON prevalence between men and women, and to a highly significant sexual dimorphism observed in metabolomics, the primary and secondary objectives will be evaluated separately according to the gender of healthy carriers and controls.
← all excerpts
MetabOCT: a clinical trial looking for a metabolomic signature predicting the onset of Leber's hereditary optic neuropathy in healthy MtDNA mutations carriers.
1
—
—